Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(24):1800-1801; doi:10.1093/jnci/dji455
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Targeting Mitochondria Emerges as Therapeutic Strategy

Ken Garber

The first 150 words of the full text of this article appear below.

For most cancer researchers, mitochondria are an afterthought. "I was brought kicking and screaming into mitochondria [research]," said Gerard Evan, Ph.D., of the University of California, San Francisco, at the 2005 annual meeting of the American Association for Cancer Research. Evan began looking at mitochondria after linking the myc oncogene to apoptosis, or programmed cell death. Others are starting to find their own paths. "All roads lead to the mitochondria," Evan added.

"It wasn't too long ago, at the major programmed cell death meetings, there would be almost no mention of mitochondria," said David Hockenbery, Ph.D., of the Fred Hutchinson Cancer Research Center in Seattle. The 1996 discovery that the protein cytochrome c acted to trigger apoptosis forced people to look at mitochondria, because that's where cytochrome c came from. "So something had to be happening at the mitochondrial level," said Hockenbery. "Since then, the field has just sort of . . . [Full Text of this Article]

Live and Let Die

Myriad of Mechanisms

Starving Tumors To Kill Them

New Metabolic Target


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Mena, M. Benlloch, A. Ortega, J. Carretero, E. Obrador, M. Asensi, I. Petschen, B. D. Brown, and J. M. Estrela
Bcl-2 and Glutathione Depletion Sensitizes B16 Melanoma to Combination Therapy and Eliminates Metastatic Disease
Clin. Cancer Res., May 1, 2007; 13(9): 2658 - 2666.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Jiang, I. Kurnikov, N. A. Belikova, J. Xiao, Q. Zhao, A. A. Amoscato, R. Braslau, A. Studer, M. P. Fink, J. S. Greenberger, et al.
Structural Requirements for Optimized Delivery, Inhibition of Oxidative Stress, and Antiapoptotic Activity of Targeted Nitroxides
J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1050 - 1060.
[Abstract] [Full Text] [PDF]